Cargando…

Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy

Immune checkpoint inhibitors (ICIs), which can enhance antitumor immunity and inhibit cancer growth, have revolutionized the treatment of multiple cancers and dramatically decreased mortality. However, treatment with ICIs is directly associated with immune-related adverse events (irAEs) because of i...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Pan, Deng, Xuan, Hu, Zhishuo, Chen, Zhe, Huang, Yao, Wang, Ke, Qin, Kai, Huang, Ying, Ba, Xin, Yan, Jiahui, Han, Liang, Tu, Shenghao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599930/
https://www.ncbi.nlm.nih.gov/pubmed/34805229
http://dx.doi.org/10.3389/fmed.2021.762247
_version_ 1784601042817646592
author Shen, Pan
Deng, Xuan
Hu, Zhishuo
Chen, Zhe
Huang, Yao
Wang, Ke
Qin, Kai
Huang, Ying
Ba, Xin
Yan, Jiahui
Han, Liang
Tu, Shenghao
author_facet Shen, Pan
Deng, Xuan
Hu, Zhishuo
Chen, Zhe
Huang, Yao
Wang, Ke
Qin, Kai
Huang, Ying
Ba, Xin
Yan, Jiahui
Han, Liang
Tu, Shenghao
author_sort Shen, Pan
collection PubMed
description Immune checkpoint inhibitors (ICIs), which can enhance antitumor immunity and inhibit cancer growth, have revolutionized the treatment of multiple cancers and dramatically decreased mortality. However, treatment with ICIs is directly associated with immune-related adverse events (irAEs) because of inflammation in off-target organs and autoimmunity resulting from non-specific immune activation. These irAEs can cause rheumatic diseases and manifestations such as inflammatory arthritis, polymyalgia rheumatica, myositis, vasculitis, Sicca and Sjogen's syndrome, and systemic lupus erythematosus. Early diagnosis and treatment of these adverse events will improve outcomes and quality of life for cancer patients. The treatment of rheumatic diseases induced by ICIs requires multidisciplinary cooperation among physicians. Furthermore, the underlying mechanisms are not fully understood and it is difficult to predict and evaluate these side effects precisely. In this review, we summarize available studies and findings about rheumatic irAEs, focusing mainly on the clinical manifestations, epidemiology, possible mechanisms, and guiding principles for treating these irAEs.
format Online
Article
Text
id pubmed-8599930
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85999302021-11-19 Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy Shen, Pan Deng, Xuan Hu, Zhishuo Chen, Zhe Huang, Yao Wang, Ke Qin, Kai Huang, Ying Ba, Xin Yan, Jiahui Han, Liang Tu, Shenghao Front Med (Lausanne) Medicine Immune checkpoint inhibitors (ICIs), which can enhance antitumor immunity and inhibit cancer growth, have revolutionized the treatment of multiple cancers and dramatically decreased mortality. However, treatment with ICIs is directly associated with immune-related adverse events (irAEs) because of inflammation in off-target organs and autoimmunity resulting from non-specific immune activation. These irAEs can cause rheumatic diseases and manifestations such as inflammatory arthritis, polymyalgia rheumatica, myositis, vasculitis, Sicca and Sjogen's syndrome, and systemic lupus erythematosus. Early diagnosis and treatment of these adverse events will improve outcomes and quality of life for cancer patients. The treatment of rheumatic diseases induced by ICIs requires multidisciplinary cooperation among physicians. Furthermore, the underlying mechanisms are not fully understood and it is difficult to predict and evaluate these side effects precisely. In this review, we summarize available studies and findings about rheumatic irAEs, focusing mainly on the clinical manifestations, epidemiology, possible mechanisms, and guiding principles for treating these irAEs. Frontiers Media S.A. 2021-11-04 /pmc/articles/PMC8599930/ /pubmed/34805229 http://dx.doi.org/10.3389/fmed.2021.762247 Text en Copyright © 2021 Shen, Deng, Hu, Chen, Huang, Wang, Qin, Huang, Ba, Yan, Han and Tu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Shen, Pan
Deng, Xuan
Hu, Zhishuo
Chen, Zhe
Huang, Yao
Wang, Ke
Qin, Kai
Huang, Ying
Ba, Xin
Yan, Jiahui
Han, Liang
Tu, Shenghao
Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy
title Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy
title_full Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy
title_fullStr Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy
title_full_unstemmed Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy
title_short Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy
title_sort rheumatic manifestations and diseases from immune checkpoint inhibitors in cancer immunotherapy
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599930/
https://www.ncbi.nlm.nih.gov/pubmed/34805229
http://dx.doi.org/10.3389/fmed.2021.762247
work_keys_str_mv AT shenpan rheumaticmanifestationsanddiseasesfromimmunecheckpointinhibitorsincancerimmunotherapy
AT dengxuan rheumaticmanifestationsanddiseasesfromimmunecheckpointinhibitorsincancerimmunotherapy
AT huzhishuo rheumaticmanifestationsanddiseasesfromimmunecheckpointinhibitorsincancerimmunotherapy
AT chenzhe rheumaticmanifestationsanddiseasesfromimmunecheckpointinhibitorsincancerimmunotherapy
AT huangyao rheumaticmanifestationsanddiseasesfromimmunecheckpointinhibitorsincancerimmunotherapy
AT wangke rheumaticmanifestationsanddiseasesfromimmunecheckpointinhibitorsincancerimmunotherapy
AT qinkai rheumaticmanifestationsanddiseasesfromimmunecheckpointinhibitorsincancerimmunotherapy
AT huangying rheumaticmanifestationsanddiseasesfromimmunecheckpointinhibitorsincancerimmunotherapy
AT baxin rheumaticmanifestationsanddiseasesfromimmunecheckpointinhibitorsincancerimmunotherapy
AT yanjiahui rheumaticmanifestationsanddiseasesfromimmunecheckpointinhibitorsincancerimmunotherapy
AT hanliang rheumaticmanifestationsanddiseasesfromimmunecheckpointinhibitorsincancerimmunotherapy
AT tushenghao rheumaticmanifestationsanddiseasesfromimmunecheckpointinhibitorsincancerimmunotherapy